A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-12-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1
receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in
participants with advanced solid tumors.